Among 3 analysts covering Alumasc Group PLC (LON:ALU), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Alumasc Group PLC had 22 analyst reports since August 5, 2015 according to SRatingsIntel. On Friday, December 4 the stock rating was maintained by FinnCap with “Buy”. The company was maintained on Wednesday, August 5 by FinnCap. The firm has “Buy” rating by Peel Hunt given on Tuesday, January 31. Peel Hunt maintained the stock with “Buy” rating in Tuesday, January 12 report. Peel Hunt maintained Alumasc Group plc (LON:ALU) rating on Friday, July 1. Peel Hunt has “Buy” rating and GBX 210 target. Peel Hunt maintained the stock with “Buy” rating in Tuesday, October 18 report. The company was maintained on Monday, February 8 by Peel Hunt. FinnCap maintained it with “Buy” rating and GBX 225 target in Thursday, October 27 report. The stock of Alumasc Group plc (LON:ALU) earned “Buy” rating by Canaccord Genuity on Monday, January 30. The firm has “Buy” rating given on Thursday, September 3 by FinnCap. See Alumasc Group plc (LON:ALU) latest ratings:
09/02/2017 Broker: Peel Hunt Rating: Buy Old Target: GBX 210.00 New Target: GBX 210.00 Maintain
31/01/2017 Broker: Peel Hunt Rating: Buy Old Target: GBX 210.00 New Target: GBX 210.00 Maintain
31/01/2017 Broker: FinnCap Rating: Buy Old Target: GBX 225.00 New Target: GBX 225.00 Maintain
30/01/2017 Broker: Canaccord Genuity Rating: Buy New Target: GBX 300.00 Initiate
19/12/2016 Broker: FinnCap Rating: Buy Old Target: GBX 225.00 New Target: GBX 225.00 Maintain
27/10/2016 Broker: FinnCap Rating: Buy Old Target: GBX 225.00 New Target: GBX 225.00 Maintain
18/10/2016 Broker: Peel Hunt Rating: Buy Old Target: GBX 210.00 New Target: GBX 210.00 Maintain
In an analyst report issued to clients by Shore Capital on 27 March, AstraZeneca PLC (LON:AZN) stock Sell was reconfirmed.
Analysts await AstraZeneca plc (ADR) (NYSE:AZN) to report earnings on May, 5. They expect $0.32 EPS, down 66.32% or $0.63 from last year’s $0.95 per share. AZN’s profit will be $798.21 million for 24.46 P/E if the $0.32 EPS becomes a reality. After $1.21 actual EPS reported by AstraZeneca plc (ADR) for the previous quarter, Wall Street now forecasts -73.55% negative EPS growth.
Among 31 analysts covering AstraZeneca PLC (LON:AZN), 16 have Buy rating, 4 Sell and 11 Hold. Therefore 52% are positive. AstraZeneca PLC has GBX 7600 highest and GBX 3700 lowest target. GBX 4917.50’s average target is -0.64% below currents GBX 4949 stock price. AstraZeneca PLC had 426 analyst reports since July 23, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Wednesday, February 22 by Berenberg. Jefferies maintained it with “Buy” rating and GBX 5400 target in Friday, January 13 report. The rating was maintained by JP Morgan with “Neutral” on Monday, August 8. Jefferies maintained it with “Buy” rating and GBX 6000 target in Thursday, October 13 report. The stock of AstraZeneca plc (LON:AZN) earned “Buy” rating by Cantor Fitzgerald on Thursday, February 2. The firm earned “Buy” rating on Wednesday, September 2 by HSBC. The firm earned “Buy” rating on Monday, February 1 by Deutsche Bank. The rating was maintained by Bernstein with “Market Perform” on Tuesday, September 22. The firm has “Outperform” rating given on Tuesday, March 8 by BNP Paribas. On Thursday, March 16 the stock rating was maintained by Beaufort Securities with “Hold”.
AstraZeneca PLC is a biopharmaceutical company. The company has market cap of 62.88 billion GBP. The Firm focuses on discovery and development of products, which are then manufactured, marketed and sold. It has a 22.32 P/E ratio. The Firm focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
About 605,079 shares traded. AstraZeneca plc (LON:AZN) has declined 0.53% since August 26, 2016 and is downtrending. It has underperformed by 7.71% the S&P500.
The Alumasc Group plc is a building products, systems and solutions company. The company has market cap of 64.05 million GBP. The Company’s divisions include, Solar Shading & Screening, Roofing & Walling, Water Management, and Housebuilding & Ancillary Products. It has a 11.54 P/E ratio. The Solar Shading & Screening segment offers Levolux’s architectural solutions, which are used to shade and screen buildings.
